Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | PRNP | P04156 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | METAP2 | P50579 | 1/20 | 0.32 |
| ▸ | CCR1 | P32246 | 2/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL315820 | 0.81 | TP53 (0.37) | SMN1; SMN2GAALMNARAB9AALDH1A1 | |
| SCHEMBL944682 | 0.79 | ALDH1A1 (0.35) | SMN1; SMN2GAALMNAALDH1A1MEN1 | |
| SCHEMBL27764064 | 0.77 | NPC1 (0.36) | SMN1; SMN2GAALMNARAB9AALDH1A1 | |
| SCHEMBL22093016 | 0.75 | NQO2 (0.47) | SMN1; SMN2GAALMNARAB9AALDH1A1 | |
| SCHEMBL5926098 | 0.70 | PARP1 (0.37) | SMN1; SMN2LMNARAB9AALDH1A1KDM4E | |
| SCHEMBL378207 | 0.68 | METAP2 (0.59) | SMN1; SMN2LMNARAB9AMEN1KMT2A | |
| SCHEMBL96433 | 0.68 | CYP1A2 (0.45) | SMN1; SMN2GAARAB9AALDH1A1KDM4E | |
| SCHEMBL22126089 | 0.68 | AR (0.37) | SMN1; SMN2GAALMNARAB9AALDH1A1 | |
| SCHEMBL19189304 | 0.64 | KDM4E (0.62) | SMN1; SMN2GAALMNARAB9AALDH1A1 | |
| SCHEMBL1090860 | 0.63 | KDM4E (0.35) | GAAALDH1A1KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3682873-B1 | SMAC MIMETICS FOR USE IN THE TREATMENT OF PERSISTENT HIV INFECTION | WALTER & ELIZA HALL INST MEDICAL RES (AU) | 2024-06-12 | — | — | EP | disclosed |
| US-11702401-B2 | Compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2023-07-18 | — | — | US | disclosed |
| US-20220000847-A1 | Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC (US) | 2022-01-06 | — | — | US | disclosed |
| US-11053216-B2 | Compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2021-07-06 | — | — | US | disclosed |
| CN-112957365-A | Methods of treating intracellular infections | 沃尔特和伊利莎豪医学研究所 | 2021-06-15 | — | — | CN | disclosed |
| CN-105451726-B | Methods of treating intracellular infections | 沃尔特和伊利莎豪医学研究所 | 2021-03-16 | — | — | CN | disclosed |
| EP-3013329-B1 | SMAC MIMETICS FOR THE TREATMENT OF PERSISTENT INTRACELLULAR HBV INFECTION | WALTER & ELIZA HALL INST MEDICAL RES (AU) | 2020-08-05 | — | — | EP | disclosed |
| CN-111481669-A | Methods of treating intracellular infections | 沃尔特和伊利莎豪医学研究所 | 2020-08-04 | — | — | CN | disclosed |
| EP-3089971-B1 | COMPOUNDS AND METHODS OF USE | MEDIVATION TECH LLC (US) | 2020-07-29 | — | — | EP | disclosed |
| EP-3682873-A1 | SMAC MIMETICS FOR USE IN THE TREATMENT OF PERSISTENT HIV INFECTION | The Walter and Eliza Hall Institute of Medical Research (AU) | 2020-07-22 | — | — | EP | disclosed |
| WO-2015017520-A1 | METHOD OF TREATMENT | TETRALOGIC PHARMACEUTICALS CORP. (US) | 2015-02-05 | — | — | WO | disclosed |
| WO-2014205516-A1 | METHOD OF TREATING INTRACELLULAR INFECTION | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2014-12-31 | — | — | WO | disclosed |
| US-20140303090-A1 | Smac Mimetic Therapy | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2014-10-09 | — | — | US | disclosed |
| WO-2014022612-A1 | COMBINATION THERAPY | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2014-02-06 | — | — | WO | disclosed |
| US-20130196927-A1 | Smac Mimetic Therapy | TETRALOGIC PHARMACEUTICALS CORPORATION | 2013-08-01 | — | — | US | disclosed |
| EP-2434889-A1 | IAP INHIBITORS | Tetralogic Pharmaceuticals Corp. (US) | 2012-04-04 | — | — | EP | disclosed |
| EP-2434890-A1 | IAP INHIBITORS | Tetralogic Pharmaceuticals Corp. (US) | 2012-04-04 | — | — | EP | disclosed |
| WO-2011068926-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORP. (US) | 2011-06-09 | — | — | WO | disclosed |
| WO-2010138496-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORP. (US) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010138666-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORP. (US) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220000847-A1 | Compounds and Methods of Use | TGFB2, TGFB1, HDGF | SMN1; SMN2 1612/4885GAA 263/4885LMNA 2845/4885 |
| US-11702401-B2 | Compounds and methods of use | TGFB2, TGFB1, HDGF | SMN1; SMN2 1612/4885GAA 263/4885LMNA 2845/4885 |
| US-20130196927-A1 | Smac Mimetic Therapy | BIRC7, BIRC2, BIRC3 | SMN1; SMN2 76/4885GAA 2299/4885LMNA 676/4885 |
| US-20140303090-A1 | Smac Mimetic Therapy | XIAP, BIRC3, BIRC5 | SMN1; SMN2 38/4885GAA 3080/4885LMNA 210/4885 |
| US-11053216-B2 | Compounds and methods of use | TGFB2, TGFB1, HDGF | SMN1; SMN2 1612/4885GAA 263/4885LMNA 2845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.